Davey M G
Med J Aust. 1975 Aug 16;2(7):263-7.
After seven years' general use of anti-Rh (D) immunoglobulin in Australia, it is clear that the rate of Rh immunization by pregnancy can be reduced to 1% or less by giving anti-D to women at risk soon after delivery. All Rh-negative women who have miscarriages or terminations of pregnancy should also be given anti-D. The Australian standard dose of 250 mug of anti-D is also much more than the minimum effective dose for most cases, and few more failures would occur if it were reduced to 100mug of antibody. Some of these may be prevented by screening maternal blood for the presence of fetal cells and giving further anti-D when large numbers are found. A trial has been conducted since 1970 to discover whether giving anti-D during pregnancy as well as at delivery will further reduce the rate of rhesus immunization. Results are still inconclusive. While giving anti-D during pregnancy appear to have no serious hazard for mother or infant, it will prevent few cases of rhesus immunization, and may not be justifiable. There has so far been little change in the incidence or mortality of haemolytic disease of the newborn in Australia that cen be attributed to the use of anti-D.
在澳大利亚对Rh(D)免疫球蛋白进行了七年的普遍使用后,很明显,通过在分娩后不久对有风险的妇女给予抗-D,可以将因怀孕导致的Rh免疫率降低到1%或更低。所有流产或终止妊娠的Rh阴性妇女也应给予抗-D。澳大利亚250微克抗-D的标准剂量也远高于大多数情况下的最低有效剂量,如果将其降低到100微克抗体,几乎不会出现更多的失败情况。其中一些情况可以通过筛查母体血液中是否存在胎儿细胞,并在发现大量胎儿细胞时给予额外的抗-D来预防。自1970年以来进行了一项试验,以确定在孕期以及分娩时给予抗-D是否会进一步降低恒河猴免疫率。结果仍无定论。虽然在孕期给予抗-D似乎对母亲或婴儿没有严重危害,但它只能预防极少数恒河猴免疫病例,可能并不合理。到目前为止,澳大利亚新生儿溶血病的发病率或死亡率几乎没有因使用抗-D而发生变化。